Ashworth, M., Lea, R., Gray, H., Rowlands, G., Gravelle, H., & Majeed, A. (2004). How are primary care organizations using financial incentives to influence prescribing? Journal of Public Health, 26(1), 48.
Bateman, D. N., Campbell, M., Donaldson, L. J., Roberts, S. J., & Smith, J. M. (1996). A prescribing incentive scheme for non-fundholding general practices: an observational study. Quality and Safety in Health Care, 313(7056), 535-538.
Blomqvist, A. (1991). The doctor as double agent: information asymmetry, health insurance, and medical care. Journal of Health Economics, 10(4), 411-432.
Bryant, J., & Prohmmo, A. (2005). Payment mechanisms and prescriptions in four Thai hospitals. Health Policy, 73, 160-171.
C.Robinson, J. (2001). The end of asymmetric information. Journal of Health Politics, Policy and Law, 26(5), 1045.
Chalkleya, M., & Khalil, F. (2005). Third party purchasing of health services: Patient choice and agency. Journal of Health Economics, 24(6), 1132-1153.
Chen, C.-L., Chen, L., & Yang, W.-C. (2008). The influences of Taiwan''s generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-used classes of cardiovascular drugs. BMC Public Health, 8.
Cheng, S. F., Hsu, H.-H., Lee, H. S., Lin, C. S., Chou, Y. C., & J.H.Tien. (2004). Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. Journal of Clinical Pharmacy and Therapeutics, 29(6), 547-558.
Chon´e, P., & Ma, C.-t. A. (2005). Asymmetric Information from Physician Agency: Optimal Payment and Healthcare Quantity. 1-37.
Chu, H.-L., Shuen-Zen, L., & James, C. R. (2008). Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the medicare system. Journal of Health Care Finance, 34(3), 45-54.
Ess, S. M., Schneeweiss, S., & Szucs, T. D. (2003). European healthcare policies for controlling drug expenditure. PharmacoEconomics, 21(2), 89-103.
Gafni, A., Charles, C., & Whelan, T. (1998). The physician–patient encounter: the physician as a perfect agent for the patient versus the informed treatment decision-making model. Social Science and Medicine, 47(3), 347-354.
Gouya, G., Berthold, R., Anja, B., Robert, W., & Michael, W. (2008). Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients. Wiener Klinische Wochenschrift / The Middle-European Journal of Medicine, 120(3-4), 89-95.
Grant, R. W., Wexler, D. J., Watson, A. J., Lester, W. T., Cagliero, E., Campbell, E. G., et al. (2007). How Doctors Choose Medications to Treat Type 2 Diabetes. Diabetes Care, 30(6), 1448-1453.
Have, P. t. (2005). Talk and Institution: A Reconsideration of the “Asymmetry” of Doctor-Patient Interaction.
Hellerstein, J. K. (1998). The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics, 29(1), 108-136.
Iizuka, T. (2008). Experts'' agency problems: evidence from the prescription drug market in Japan. RAND Journal of Economics, 38(3), 1-25.
Lee, Y.-C., Huang, K.-H., & Huang, Y.-T. (2007). Adverse pharmaceutical payment incentives and providers'' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan. Health Policy and Planning, 22(6), 427-435.
Lee, Y.-C., Yang, M.-C., Huang, Y.-T., Liu, C.-H., & Chen, S.-B. (2006). Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 19962003. PharmacoEconomics, 24(9), 891-902.
Liu, Y.-M., Yang, Y.-H. K., & Hsieh, C.-R. (2009). Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan. Journal of Health Economics, 28(2), 341-349.
Lo, J. C. (2003). Patients'' attitudes vs. physicians'' determination: implications for cesarean sections. Social Science and Medicine, 57(1), 91-96.
Lundin, D. (2000). Moral hazard in physician prescription behavior. Journal of Health Economics, 19(5), 639-662.
McAdams, D. (2006). Perverse Incentives in the Medicare Prescription Drug Benefit. NBER Working Papers, 1-19.
McGuire, T. G. (2000). Physician agency In: Handbook of Health Economics. 1A. North Holland, Amsterdam.
Mrazek, M. F., & Mossialos, E. ( 2000). Increasing demand while decreasing costs of generic medicines. the lancet, 356, 1784-1785.
Pauly, M. V. (1988). Is medical care different? Old questions, new answers. Journal of Health Politics, Policy and Law, 13(2), 227-237.
Pitt, B. (2004). Generic drugs in cardiology: will they reduce health care costs? Journal of the American College of Cardiology, 44(1), 10-13.
Robinson, J. C. (2001). Theory and practice in the design of physician payment incentives. Milbank Quarterly, 79(2), 149-177.
Rochaix, L. (1989). Information asymmetry and search in the market for physicians'' services. Journal of Health Economics, 8(1), 53-84.
Rodwin, M. A. (2004). Financial incentives for doctors. BMJ (Clinical Research Ed.), 328(7452), 1328-1329.
Schumock, G. T., & Surrey, M. W. (2003). Expenditures for prescription drugs: too much or not enough? Healthcare Financial Management, 57(10), 34-41.
Shortell, S. M., Waters, T. M., & Clarke, K. W. B. (1998). Physicians as double agents: maintaining trust in an era of multiple accountabilities. Journal of the American Medical Association, 280(12), 1102-1108.
Stern, S. (1998). Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking. NBER Working Papers, 1-30.
Vardy, D. A., Refael, K., & Eliezer, K. (2008). [Physician incentives--an overview]. Refuah, 147(12), 999-1027.
Yip, W. C. (1998). Physician response to Medicare fee reductions: changes in the volume of coronary artery bypass ž. Journal of Health Economics, 17, 675-699.
Young, B. A., Elizabeth, L., Michael Von, K., Greg, S., Paul, C., & Evette, J. L. (2008). Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. American Journal of Managed Care, 14(1), 15-23.
中央健康保險局-主題專區-醫療品質資訊公開. (2005). 全民健保糖尿病病人2001-2003年醫療資源利用分析.
全民健康保險網站. (2007). 全民健康保險辦理藥品給付、價格訂定及調整Q&A.
江瑞坤, 劉鎮嘉, & 顏韶宏. (2006). 糖尿病口服用藥. 基層醫學, 21(2), 43-47.李宗蓁. (2006). 藥價政策對於處方行為及病人權益影響之研究— 以抗憂鬱劑為例 .
李哲全, 傅振宗, & 吳篤安. (2006). 糖尿病的診斷與治療. 慈濟醫學雜誌, 18, 1-9.周碧瑟, 董道興, 李佳琳, 莊紹源, 林敬恆, & 楊南屏. (2002). 台灣地區糖尿病流行病學. 臺灣公共衛生雜誌, 21(2), 83-96.邱亨嘉. (2001). 醫院藥品政策和醫師行為對健保醫療藥價之影響. 行政院衛生署委託研究計畫.
財團法人台灣醫療改革基金會. (2007). 961104呼籲衛生署將150億還給民眾,透明費協會決筞過程
高建仁, 高東煒, 陳永煌, 周稚傑, 劉紹興, & 羅慶徽. (2005). 從全民健保資料分析糖尿病病患之流行病學與用藥情形. 中華職業醫學雜誌, 12(3), 187-195.健保小組. (2007). 全民健康保險辦理藥品給付、價格訂定及調整Q&A.
張鴻仁. (2001). 全民健保藥價給付政策」.
陳建良, & 謝昌勳. (2008). 第 2 型糖尿病之藥物. 臺灣醫學, 12(2), 231-238.陳清芳. (2008). 去年降血壓藥依舊暢銷 癌症新藥來勢洶洶. 中央社報導.
程馨, & 謝啟瑞. (2005). 全民健保藥品政策與藥品費用的經濟分析. 經社法制論叢, 35, 1-42.傳振宗. (2006). 糖尿病的藥物治療. 健康世界(243), 23-29.
盧瑞芬, & 謝啟瑞. (2000). 醫療行銷學. 書籍.
賴美淑, 鄭守夏, 魏玉容, & 徐慧君. (2005). 不同醫療體系因應SARS 危機動員制度之評估(子計畫五). 行政院國家科學委員會補助專題研究計畫, 1-70.
謝維清. (1990). 治療糖尿病口服藥物. 慈濟醫學雜誌, 2(6), 539-540.
譚令蒂, 洪乙禎, & 謝啟瑞. (2007). 論藥價差. 經濟論文叢刊, 35(4), 451-476.